Please log in to determine if you are eligible to purchase PT Programs.
TROPONIN TURNAROUND TIMES - QT15
QT15

Patients presenting to the emergency department (ED) with chest pain must be evaluated quickly. Rapid serum troponin measurement is an important part of ED practice that can provide decisive information for patient management. Reducing delays in troponin testing has been reported to result in shorter length of stay in the ED and more rapid initiation of anti-ischemic treatment. Emergency departments and chest pain centers should, therefore, have effective procedures for ensuring optimal turnaround time (TAT) for troponin testing and a process for ongoing monitoring to ensure that performance meets expectations.

QT15 is enhanced for 2019 with additional time intervals to help pinpoint process time challenges. Laboratories use this monitor to help meet CAP Laboratory Accreditation Program Checklist statement GEN.20316 QM Indicators of Quality. The American College of Cardiology and the American Heart Association recommend troponin as the preferred diagnostic biomarker in their Acute Coronary Syndromes guideline.


Objective

This study will assist participating laboratories to determine and monitor:

  • The median TATs for processes from order time through result availability, with up to five times intervals within the total testing process
  • The percent compliance for troponin results with their institution's established deadline

Data Collection

Six days per month, collect data from nine patients presenting to the ED with chest pain and tested for troponin level. Data includes time of troponin test order, specimen collection, laboratory receipt, and result availability. Participants are not required to provide data from each TAT component. Participants will select TAT metrics that they wish to monitor, with the option to monitor all metrics.

Participants will also complete a questionnaire about clinical and laboratory practices related to troponin testing.

Performance Indicators

Median TATs for the following time intervals:

  • Test order to specimen collection
  • Specimen collection to laboratory receipt
  • Laboratory receipt to result availability
  • Specimen collection to result availability
  • Test order to result availability

Compliance (%) with institutional threshold for the following time intervals:

  • Specimen collection to result availability
  • Test order to result availability

Shipping Schedule

  • Shipment A: December 3, 2018
  • Shipment B: March 4, 2019
  • Shipment C: June 3, 2019
  • Shipment D: September 3, 2019

Additional Information

Participants in the Q-TRACKS program receive:

  • Users Guide
  • Templates and instructions for data collection
  • Quarterly reports that include fingerprint clusters, customer-defined groups, and all institution comparisons
  • Peer directory

Q-TRACKS activities meet the American Board of Pathology MOC Part IV Practice Performance Assessment requirements.

For Comprehensive Collection of Tools, see Quality Management Tools.


 
Select Q-PROBES and Q-TRACKS studies to support your quality improvement initiatives.
Preanalytic
Analytic
Postanalytic
Anatomic Pathology
Clinical Pathology
Turnaround Time
Patient Safety
Microbiology
Transfusion Medicine
Chemistry/ Hematology
Customer Satisfaction
Q-PROBES
Technical Staffing Ratios (QP191)
Opioid Drug Testing Stewardship (QP192)
Expression Rates in Invasive Breast Carcinoma (QP193)
The Impact of Pathologist Review on Peripheral Blood Smears (QP194)
Q-TRACKS
Patient Identification Accuracy (QT1)
Blood Culture Contamination (QT2)
Laboratory Specimen Acceptability (QT3)
In-Date Blood Product Wastage (QT4)
Gynecologic Cytology Outcomes: Biopsy Correlation Performance (QT5)
Satisfaction With Outpatient Specimen Collection (QT7)
Stat Test Turnaround Time Outliers (QT8)
Critical Values Reporting (QT10)
Troponin Turnaround Times (QT15)
Corrected Results (QT16)
Outpatient Order Entry Errors (QT17)

*The CAP requires accredited laboratories to have a quality management plan that covers all areas of the laboratory and includes benchmarking key measures of laboratory performance (GEN.13806, GEN.20316, COM.04000). The Joint Commission requires accredited hospitals to regularly collect and analyze performance data (PI.01.01.01, PI.02.01.01). CLIA requires laboratories to monitor, assess, and correct problems identified in preanalytic, analytic, and postanalytic systems (§493.1249, §493.1289, §493.1299).